Oncology

DNA research molecule
#CAR-T #DNA #Epigenomics #Genetic editing #Genomics #Immunology #Oncology #Tune Therapeutic

Moving the needle of CAR-T beyond oncology 

CAR-T Therapies have revolutionised the field of personalised medicine, especially in oncology. DDW’s Megan Thomas speaks with Dr Blythe Sather, Vice President and Head of Research at Tune Therapeutics, about how genetic tuning will transform the reach for CAR-T therapies, the different diseases that can benefit, and the disruptive technology… Read More

#Cancer Research #Exclusive Content

Non-small cell lung cancer
#AstraZeneca #FDA #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Combination therapy reduced risk of lung cancer progression by 38%

The US Food and Drug Administration (FDA) has approved AstraZeneca’s osimertinib (Tagrisso) as a treatment for locally advanced or metastatic non-small cell lung cancer (la/mNSCLC). It is approved in combination with platinum-based chemotherapy for patients with la/mNSCLC whose tumours have EGFR exon 19 deletions or exon… Read More

#News #Regulatory

#Cancer research #Career #Harvard Medical School #Interview #Meet the Researcher #Oncology

Meet the researcher: Jenny Hogstrom-Stakem

Jenny Hogstrom-Stakem, Postdoctoral Research Fellow, was recently awarded the 2023 AACR-AstraZeneca Breast Cancer Research Fellowship. Here she shares her career highlights and advice with DDW’s Diana Spencer. DS: Can you tell us what you do and what you’re working on at the moment? JHS:… Read More

#Exclusive Content

MRI showing glioblastoma
#Brain cancer #Oncology #Phase I trial #The Institute of Cancer Research #The Royal Marsden NHS Foundation Trust

‘Olive oil’ drug shows early promise in brain cancer

A drug derived from oleic acid – which naturally occurs in animal and vegetable fats such as olive oil – has shown promise for patients with brain cancer, following a study led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK. Results… Read More

#Cancer Research #News

T cells attacking cancer
#Cell and gene therapy #Cell therapy #FDA #Iovance #Melanoma #Oncology #Solid tumours

FDA approves first T cell therapy in solid tumours

The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. It is approved for use in adults that have previously been treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a… Read More

#News #Regulatory #Trending News

Cancer research
#Cancer research #DDW Turning Science into Business Summit #Events #Immuno-oncology #Oncology

DDW Turning Science into Business Summit: Cancer research

DDW recently hosted an online event, sponsored by Taconic Biosciences, which outlined areas of advancement and opportunity in the cancer research market. Megan Thomas summarises the key points examined by the participating experts. New drug discovery and development concepts The event started with a panel discussion… Read More

#Cancer Research #Exclusive Content

Researcher loads DNA samples for PCR analysis
#AI / data analytics / healthtech / informatics #Oncology #Queen's University Belfast #RNAi #TechBio

Belfast techbio raises £1.4m to tackle complex diseases

Belfast-based techbio company AMPLY Discovery has raised over £1.4 ($1.7) million in grant funding to develop new drugs using its AI-driven drug discovery platform. The company, which is a spin-out from the Queen’s University Belfast, was established in 2021 to commercialise a drug discovery platform developed… Read More

#Business & Investment #News

Peptide
#Endocrinology #FDA #Oncology #Orano Med #RadioMedix #Radiopharmaceuticals

First targeted alpha therapy receives breakthrough designation

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to AlphaMedix (212Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumours (GEP-NETs) who are naïve to peptide receptor radionuclide therapy (PRRT). AlphaMedix is a targeted… Read More

#Cancer Research #News #Regulatory

Blood cancer
#Blood cancer #Gene mutation #Nurix Therapeutics #Oncology #Protein degradation

Protein degrader overcomes resistance in B-cell malignancies

A paper in the journal Science has identified a new class of BTK mutations that are susceptible to NX-2127, a novel BTK and IKZF1/3 degrader.  The study ‘Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127’ elucidates a previously unappreciated oncogenic scaffold function… Read More

#Cancer Research #News

#Arvinas #Breast cancer #FDA #Oncology #Pfizer #PROTAC #Protein degradation

PROTAC degrader for ER+/HER2- breast cancer gets fast-tracked

Arvinas and Pfizer’s vepdegestrant (ARV-471) has received Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of patients with ER+/HER2- metastatic breast cancer. Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the estrogen receptor… Read More

#Cancer Research #News #Regulatory

Bladder
#Astellas Pharma #Bladder cancer #Japan #Oncology #Regulatory #Urothelial carcinoma

Japanese regulator reviews first-line bladder cancer combination

Astellas has submitted a supplemental new drug application (sNDA) in Japan for Padcev (enfortumab vedotin (genetical recombination)) with Keytruda (pembrolizumab (genetical recombination)) for the first-line treatment of advanced bladder cancer. If approved, it would be the first combination in Japan to offer an alternative to chemotherapy,… Read More

#News #Regulatory

Vaccine vial and syringe
#Cancer vaccine #Imperial College London #Moderna #mRNA-based vaccines #Oncology #Phase I trial

First UK patients receive experimental mRNA therapy for cancer

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The Mobilize trial is run in partnership between Imperial College London and… Read More

#Cancer Research #News #Trending News

2024 predictions, road forward
#2024 predictions #AstraZeneca #BioSenic #Cancer #Drug discovery #Mosaic Therapeutics #Oncology #OrganaBio #Phesi #Therapeutics

2024 predictions: Experts weigh in on cancer research

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on what to expect from cancer research and immunotherapies. Greg Rossi, Senior Vice… Read More

#Cancer Research #Exclusive Content #Opinion #Trends & Analysis

#Bispecific Antibodies #Blood cancer #Cancer research #CAR-T #JAK inhibitor #Oncology

This week in drug discovery (29 January – 2 February) 

News round-up for 29 January – 2 February by DDW Digital Content Editor Diana Spencer. Sunday 4 February is World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC), so the round-up this week will focus on oncology, including the UK approval of… Read More

#News

CAR-T therapy
#CAR-T #Cell and gene therapy #Cell therapy #Immunotherapy #Kyverna Therapeutics #Oncology

Novel CAR T-cell vein-to-vein process could reduce time and cost

A paper in BioRxiv has described a new process that could improve the chimeric antigen receptor (CAR) T-cell patient experience and reduce costs through a minimisation of the CAR T-cell therapy vein-to-vein process. The process utilises less than 300ml of whole blood from a blood draw… Read More

#Cancer Research #News

Stamp of approval
#Blood cancer #GSK #MHRA #Oncology #Rare disease

JAK inhibitor for rare blood cancer approved in Great Britain

GSK’s Omjjara (momelotinib) has been granted marketing authorisation in Great Britain for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. It is approved in patients who… Read More

#News #Regulatory